BD ProbeTec Chlamydia trachomatis (CT) Qx Assay and the BD ProbeTec Neisseria gonorrhoeae (GC) Qx Assay 의 안전성 경고

Department of Health에 따르면, 해당 안전성 경고 는 Hong Kong 에서 BD 에 의해 제조된 제품과 관련되어 있습니다.

이것은 무엇인가요?

안전성 경고는 의료기기 제품과 관련된 중요한 정보와 권고사항을 담고 있습니다. 물론 안전성 경고가 배포되었다고 해서 해당 제품이 무조건 안전하지 않은 제품이라는 것은 아닙니다. 보건의료업계 종사자와 의료기기 사용자들에게 배포되는 안전성 경고에는 회수(recall)도 포함될 수 있습니다. 제조사가 안전성 경고를 작성하기도 하지만, 보건당국에서 작성하는 경우도 있습니다.

데이터에 대해 더 자세히 알아보기 여기
  • 사례 유형
    Safety alert
  • 날짜
    2014-11-14
  • 사례 출판 날짜
    2014-11-14
  • 사례 국가
  • 사례 출처
    DH
  • 사례 출처 URL
  • 비고 / 경고
    Hong Kong data is current through September 2018. All of the data comes from the Department of Health (Hong Kong), except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Hong Kong.
  • 데이터 추가 비고
    Medical Device Safety Alert
  • 원인
    Medical device safety alert: bd probetec chlamydia trachomatis (ct) qx assay and the bd probetec neisseria gonorrhoeae (gc) qx assay medical device manufacturer, bd, has issued a field correction action concerning the bd probetec chlamydia trachomatis (ct) qx assay with catalogue number 442959 and the bd probetec neisseria gonorrhoeae (gc) qx assay with catalogue number 442842. the manufacturer has learned that some customers performing the bd probetec chlamydia trachomatis (ct) qx assay and the bd probetec neisseria gonorrhoeae (gc) qx assay with the viper lt instrument are experiencing a higher than expected rate of positive test results (i.E., increased prevalence). this observation is limited to a subset of test results obtained from specimens yielding “max rfu” values in the approximate range of 125 to 250. this includes occasionally obtaining positive results for the assay negative control. based on internal investigations to date, the manufacturer has confirmed that this change in test performance is attributable to an increase in false positive results. the anomaly only impacts ct/gc assay results on the viper lt. the manufacturer will provide affected users with alternative testing methods until the issue of false positive results is addressed. the manufacturer’s representatives will contact users directly to determine which methods/options would be the most viable to satisfy their testing needs. the interim solutions include testing on an alternate platform (viper xtr, probetec, or a competitor’s instrument) or sending the ct/gc testing out to alternate laboratories. according to the manufacturer, the affected products were distributed in hong kong. if you are in possession of the affected product, please contact your supplier for necessary actions. posted on 14 november 2014.

Device

  • 모델명 / 제조번호(시리얼번호)
  • 제품 설명
    Medical Device Safety Alert: BD ProbeTec Chlamydia trachomatis (CT) Qx Assay and the BD ProbeTec Neisseria gonorrhoeae (GC) Qx Assay
  • Manufacturer
    BD

Manufacturer

BD